Imbruvica Side Effects

Generic Name: ibrutinib

Note: This page contains side effects data for the generic drug ibrutinib. It is possible that some of the dosage forms included below may not apply to the brand name Imbruvica.

It is possible that some side effects of Imbruvica may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

For the Consumer

Applies to ibrutinib: oral capsule

Along with its needed effects, ibrutinib (the active ingredient contained in Imbruvica) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ibrutinib:

More common
  • Bladder pain
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • bloody or black, tarry stools
  • bloody or cloudy urine
  • blurred vision
  • body aches or pain
  • chest pain
  • chills
  • confusion
  • cough or hoarseness
  • decreased frequency or amount of urine
  • difficult, burning, or painful urination
  • dizziness or lightheadedness
  • dry mouth
  • fainting
  • fever
  • frequent urge to urinate
  • increased thirst
  • irregular heartbeat
  • itching
  • loss of appetite
  • lower back or side pain
  • nausea and vomiting
  • rapid weight gain
  • severe headache
  • severe stomach pain
  • shortness of breath or troubled breathing
  • sore throat
  • tightness of the chest or wheezing
  • tingling of the hands or feet
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight gain or loss
  • vomiting of blood or material that looks like coffee grounds
  • warmth on the skin
  • weight gain
  • wrinkled skin
Less common
  • Persistent non-healing sore
  • pink skin growth
  • reddish skin patch or irritated area
  • shiny skin bump
  • white, yellow or waxy scar-like area on the skin

Some side effects of ibrutinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Belching
  • decreased appetite
  • difficulty having a bowel movement (stool)
  • heartburn or indigestion
  • indigestion
  • joint or muscle pain
  • lack or loss of strength
  • muscle stiffness or spasms
  • rash
  • small red or purple spots on the skin
  • stomach discomfort, upset, or pain
  • swelling or inflammation of the mouth

For Healthcare Professionals

Applies to ibrutinib: oral capsule


The most commonly occurring adverse reactions were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting, decreased appetite, pyrexia, arthralgia, stomatitis, sinusitis, and dizziness.


Very common (10% or more): Bruising (30% to 54%), rash (25% to 27%), skin infections (14% to 17%), petechiae (11% to 17%), laceration (up to 10%)


Very common (10% or more): Diarrhea (51% to 63%), nausea (21% to 31%), constipation (23% to 25%), abdominal pain (24%), vomiting (23%), stomatitis (17% to 21%), dyspepsia (11% to 13%)


Very common (10% or more): Decreased platelets (57% to 71%), decreased neutrophils (47% to 54%), decreased hemoglobin (41% to 44%)
Common (1% to 10%): Subdural hematoma (up to 4%)


Very common (10% or more): Decreased appetite (17% to 21%), hyperuricemia (up to 15%), dehydration (up to 12%)


Very common (10% or more): Musculoskeletal pain (27% to 37%), muscle spasms (14% to 19%), arthralgia (11% to 23%)

Nervous system

Very common (10% or more): Dizziness (14% to 21%), headache (13% to 19%), peripheral neuropathy (up to 10%)


Very common (10% or more): Fatigue (31% to 41%), peripheral edema (23% to 35%), pyrexia (up to 25%), asthenia (13% to 14%), chills (up to 13%)


Very common (10% or more): Upper respiratory tract infection (34% to 48%), dyspnea (10% to 27%), cough (19%), epistaxis (up to 11%), pneumonia (10% to 14%), sinusitis (13% to 21%)


Very common (10% or more): Urinary tract infection (10% to 14%)


Very common (10% or more): Second malignancies (up to 10%)


Very common (10% or more): Hypertension (up to 17%)

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.